Jean-Yves Bonnefoy as its new Chief Scientific Officer.4 million , up 8% on a constant exchange rate basis.0%) 2.5
North America 1. Sustained growth in sales and
profit validate the Group's marketing strategy and its technological
positioning .
In Asia, sales were virtually unchanged.

Average Billable Utilization Inter-contracts Technical
workforce rate rate rate (1) outsourcing
size (billable (billable (EUR
staff as days thousands)
a % of billed )
total
staff)
2004 Q1 875 78.0% 3.3% 3. In
light of the limited impact of the application of IFRS standards , the profit
from operations under IFRS should be similar to the operating profit arising
from the use of French GAAP.

reference miquelon

2005 2nd Quarter Group Sales(*) up by 8% to EUR 25.1% 19.3% 13.5 (6.0%) (6.1% 18.6%) (1.5% 2.3% 10.9 13.8% 78.
The Group forecasts for the 2nd quarter of 2005 a profit from operations
double that achieved in the previous quarter.silicomp.

collectivity territorial

7% to EUR 25.6 22.5 6.0% 43.6 18.1 % 31.7% 1.3
Asia 4.5 11.3 1.5
international
Group 1st half-year 48.1% for the 1st half-year. The value of new Engineering business sales
orders for the 1st half-year ending 30 June 2005 was up nearly 19% over the
same period last year. The
Consulting business reported a significant return to profitability in a
stable sales environment. Sales activity remained
sustained, with a well filled prospects pipeline, which, however, was
cyclical due to the significance of contracts undertaken.0% NC
(1) French Engineering operations

The Board of Directors will approve the quarterly accounts on 15
September 2005.
The 3rd quarter for 2005 will be marked by a seasonality equivalent to
that experienced in 2004 .

territorial geographic

"We are delighted to integrate Jean-Yves' immunology experience and background
in the infectiology and oncology fields.4 Million (up 14%
Under French GAAP)

Profit Forecast to Increase Significantly

MONTBONNOT SAINT MARTIN, France, Groupe
Silicomp (Paris FR0000063794) - 2005 Q2 Group sales, under IFRS, increased by
7.4
Q2 25.6 7.3 2.5
Networks 9.0% 6.2
Switzerland / 5.8%) 6.0
sales

As previously announced, 2005 2nd quarter sales growth was less sustained
than in the previous quarter due to a less favourable comparison basis as
well as a result of a cyclical and non-recurring slowdown of major
infrastructure projects deliveries in Asia.7% for the 2nd quarter
and 18.
Groupe Silicomp reported a modest increase in Group workforce to 946
during the 2nd quarter of 2005.3% 4.fr/fr/finance/Silicomp_Passage_IAS-IFRS.
Shares of Groupe Silicomp (ISIN code: FR000063794 ) trade on the Euronext
Paris Stock Exchange (Eurolist C) since 16 June 1998.

pierre miquelon

STRASBOURG, France , Transgene
(Nasdaq: TRGNY; Euronext: FR0005175080) announced today the appointment of Dr.
For the six months ended 30 June 2005, Group sales are up by nearly 14%
under IFRS and 18% under French GAAP.4 19.4
Consulting 2.6 43.3 24.8 42. The Group's Networks business reported a strong
expansion, with the value of new sales orders up 52% during this time .8% 4,978

2005 Q1 931 79.

saint territorial

Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific Officer

From 1997 to 2002, he was Director of the
Immunology Center of the Pierre Fabre Group in Saint-Julien en Genevois,
France. His arrival will allow us to
reinforce Transgene as a company dedicated to therapeutic vaccination.3% 22.0 (0.
In North America, a slight growth in sales was recorded, primarily due to
Canadian operations. The inter-contracts rate decreased to 4% from
6% for the previous quarter.0% 6. The Group's unique know-how for developing communicating
systems for your future needs are reflected in its control and integration of
network systems , industrial applications and real time, on-board computing.
With a presence on three continents, Groupe Silicomp is the preferred partner
of major manufacturers.fr

flags saint

Transgene has five products in clinical
development, two of which are in Phase II clinical trials, two in Phase I/II
and one that has completed Phase I clinical trial.

Profit
from operations for the 2nd quarter ended 30 June 2005 is forecast to be
double that realised in the 1st quarter of 2005 .

(EUR millions) 2005 2004 (% change) 2004
(IFRS) (IFRS) (French
Actual Like-for-like GAAP)
Analysis of Group sales by quarter

Q1 23.3 21.6
Sub-total France 37.9% 27.0%) 3.0% 4.6% 75.0% 3,078
Q4 920 79.
2005 Full Year Outlook
Groupe Silicomp has set as two objectives for 2005: organic sales growth
rate double that of the sector and an operating profit margin of 5% to 7%. The Group is active in
consulting and implementation services, and is a recognised specialist in
computer security.

territorial reference

Prior to joining Transgene , Jean-Yves Bonnefoy, 45, was Head of the
Canceropole Lyon Rhones-Alpes.
"We thank Serge Braun for his contribution to the development of
Transgene," stated Philippe Archinard, Chief Executive Officer of Transgene."

About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines,
immunotherapy products, and delivery technologies for the treatment of
diseases for which there is no cure or adequate treatment at present, with a
focus on the treatment of cancer.4 23.7% 8.5 13.6 1.9 6.0% 76.0% 4,958
Q2 946 80.
Please note that all information relative to the impact of the
application of IFRS standards on the accounts of Groupe Silicomp is disclosed
in French at http://www.
Next release on 22 September: 2005 1st half-year results under IFRS
About Groupe Silicomp
Groupe Silicomp is a leading Information Technology Solutions provider of
innovative, high-technology content solutions.
Visit our web site at http://www.silicomp.

collectivity pierre

He previously was responsible for the Immunology Department of the
Biomedical Research Institute of the Glaxo-Wellcome Group in Geneva,
Switzerland. Jean-Yves Bonnefoy holds a PhD in immunology from the Lyons
Claude Bernard University and has completed the Senior Management Program of
the London Business School. Transgene's proprietary
vector technology platform consists of adenovirus and poxvirus vector
families.

Groupe Silicomp: 7th Consecutive Quarter of Profitable Growth

6

Analysis of Group sales by business segment and geographic region

Engineering 25.0 4.1 (2.6%) (0.
In France, sales growth remained sustained , up 15.9% 2,689
Q2 886 78.2% 3,292
Q3 896 79.5% 76.

geographic collectivity

He replaces Serge
Braun who has decided to pursue other opportunities outside of the Company.0% 21.0% 22.3 31.0
Belgium
Sub-total - 11 .7% 13.9% 42.8% 3.2% 70.0% 77.pdf (free
translation to be released before September 2005).